ManageEngine RecoveryManager Plus
RecoveryManager Plus keeps widening its backup coverage across the Microsoft identity estate.
Comparison · Analytics
ApexCharts vs DoseFinding
A side-by-side editorial comparison of ApexCharts and DoseFinding — release velocity, themes, recent moves, and the top alternatives to consider.
ApexCharts vs DoseFinding: at a glance
What is ApexCharts?
Licensing settled, ApexCharts is back to changing what a chart can take as input.
ApexCharts is deep into a fast v6 line, shipping roughly weekly. The licensing arc that dominated 6.5 through 6.7 — trial watermarks, the first premium-gated chart type, then entitlement checks — has settled, and the last three releases are library work again. 6.9.0 is the largest of them: a histogram type that bins raw samples, a morph engine that conserves marks across chart types, and the end of the library's dependency-free packaging.
What is DoseFinding?
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
ApexCharts vs DoseFinding: editorial side-by-side
ApexCharts
10.0ANALYTICS
Licensing settled, ApexCharts is back to changing what a chart can take as input.
◆ Current state
ApexCharts is deep into a fast v6 line, shipping roughly weekly. The licensing arc that dominated 6.5 through 6.7 — trial watermarks, the first premium-gated chart type, then entitlement checks — has settled, and the last three releases are library work again. 6.9.0 is the largest of them: a histogram type that bins raw samples, a morph engine that conserves marks across chart types, and the end of the library's dependency-free packaging.
◆ Where it's heading
The through-line now is input and arrangement rather than catalogue size. Charts increasingly accept the measurements a team actually has instead of pre-aggregated values, and the seams that let you hand a chart its own layout — plotOptions.unit.positions, the pluggable layout hook — are being filled in with kits rather than hard-coded options. The premium boundary has stopped moving; the free catalogue keeps growing around it.
◆ Prediction
Expect the raw-observation pattern to reach another chart type now that the bar pathway handles binning, and expect the remaining pluggable seams to get companion kits the way positions just did.
DoseFinding
0.0ANALYTICS
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
◆ Current state
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
◆ Where it's heading
The pattern before the handover was maintenance — R-devel compliance, a bug fix, a link. After it, each release carries a named methodological addition with an acknowledged contributor, plus documentation to match: a longitudinal analysis vignette shipped alongside the interim power work. Housekeeping continues underneath, mostly clearing deprecated ggplot2 interfaces, aes_string in one release and qplot in the next.
◆ Prediction
Given the last two releases each added one method with a supporting vignette, expect the next to follow the same shape. Both additions so far extend the package beyond fixed dose-response fitting, so adaptive and interim methodology is the more likely direction.
Alternatives to ApexCharts and DoseFinding
Other Analytics products tracked by Sparkpulse, ranked by recent ship velocity. Each card links to a full editorial trajectory and lets you pivot into a head-to-head comparison with either ApexCharts or DoseFinding.
Omni
Omni ships weekly, and almost every week the headline item is an AI feature.
silx
silx settles into maintenance a release after its PySide6 migration
Plotly
Plotly is turning its cloud into a metered compute platform with an enterprise on-ramp.
aniread
aniread stops asking you to know which tracker wrote the file
Rho
Rho's release machinery finally produced a stable build — and it shipped no new product.
See all ApexCharts alternatives → · See all DoseFinding alternatives →
Recent activity from ApexCharts and DoseFinding
Latest ship moves from both products, interleaved chronologically. ⚡ = editorial spark.
- 1d agoApexChartsUnit charts get a 39-shape companion kit
- 2d agoApexChartsHistogram bins raw samples; charts morph between types ⚡
- 9d agoApexChartsPer-data-point label offsets land as functions
- 10d agoApexChartsPie and donut slice clicks work again after a 6.7.0 regression
- 16d agoApexChartsSunburst charts arrive; premium features now need an entitled plan ⚡
- 22d agoApexChartsUnit chart is the first premium-gated chart type ⚡
- 1y agoDoseFindingConditional and predictive power for interim analyses
- 1y agoDoseFindingModel averaging arrives for dose-response fitting ⚡
- 1y agoDoseFindingPackage moves to openpharma under new maintainership
- 2y agoDoseFindingCompliance update for R-devel
- 3y agoDoseFindingpowMCTBinCount bug fix
Frequently asked questions
What is the difference between ApexCharts and DoseFinding?
They serve adjacent needs but don't currently overlap on shipped themes. ApexCharts is currently shipping more aggressively (velocity 10.0 vs 0.0), with 3 editorial sparks in the last 30 days against 0. See the at-a-glance table above for a side-by-side breakdown of velocity, recent sparks, and editorial themes.
Is ApexCharts better than DoseFinding?
Sparkpulse doesn't pick a winner — we score release velocity, not feature parity. ApexCharts is currently shipping more aggressively (velocity 10.0 vs 0.0), with 3 editorial sparks in the last 30 days against 0. For your specific use case, the alternatives sections above list other Analytics products to evaluate alongside.
What are the best alternatives to ApexCharts?
Top ApexCharts alternatives in Analytics are ranked by recent ship velocity. Browse the "ApexCharts alternatives" section above for the current picks, or visit /alternatives/apexcharts for the full list with editorial commentary on each.
What are the best alternatives to DoseFinding?
Top DoseFinding alternatives in Analytics are ranked by recent ship velocity. Browse the "DoseFinding alternatives" section above for the current picks, or visit /alternatives/dosefinding for the full list with editorial commentary on each.